EGFR and non-small cell lung carcinoma: Osimertinib (AZD9291), a third-generation EGFR tyrosine kinase inhibitor (TKI) approved for the treatment of EGFR-mutated NSCLC, has been characterized as an LSD1 inhibitor with an IC50 of 3.98 ± 0.3 μM, and has demonstrated LSD1 inhibition at the cellular level [56].